Geode Capital Management
FHTX icon

Geode Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

Geode Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.45M Buy
910,866
+62,694
+7% +$278K ﹤0.01% 2976
2026
Q1 		$4.06M Buy
848,172
+53,132
+7% +$292K ﹤0.01% 2847
2025
Q4 		$4.29M Sell
795,040
-13,448
-2% -$61K ﹤0.01% 2853
2025
Q3 		$3.95M Buy
808,488
+814
+0.1% +$4.32K ﹤0.01% 2904
2025
Q2 		$3.8M Buy
807,674
+116,979
+17% +$489K ﹤0.01% 2873
2025
Q1 		$2.52M Buy
690,695
+7,832
+1% +$35.7K ﹤0.01% 2954
2024
Q4 		$3.22M Buy
682,863
+5,477
+0.8% +$39.9K ﹤0.01% 2952
2024
Q3 		$6.31M Buy
677,386
+146,276
+28% +$1.06M ﹤0.01% 2640
2024
Q2 		$3.05M Buy
531,110
+82,699
+18% +$493K ﹤0.01% 2975
2024
Q1 		$3.01M Buy
448,411
+61
+0% +$339 ﹤0.01% 2943
2023
Q4 		$2.89M Buy
448,350
+22,268
+5% +$96.1K ﹤0.01% 2971
2023
Q3 		$2.13M Buy
426,082
+19,534
+5% +$151K ﹤0.01% 3060
2023
Q2 		$2.86M Buy
406,548
+20,540
+5% +$144K ﹤0.01% 2988
2023
Q1 		$2.39M Buy
386,008
+15,759
+4% +$103K ﹤0.01% 2952
2022
Q4 		$2.36M Buy
370,249
+1,622
+0.4% +$12.2K ﹤0.01% 2974
2022
Q3 		$3.16M Buy
368,627
+12,120
+3% +$156K ﹤0.01% 2914
2022
Q2 		$4.85M Buy
356,507
+6,323
+2% +$81.6K ﹤0.01% 2714
2022
Q1 		$5.33M Buy
350,184
+2,789
+0.8% +$38.3K ﹤0.01% 2764
2021
Q4 		$7.94M Buy
347,395
+74,688
+27% +$1.07M ﹤0.01% 2606
2021
Q3 		$3.8M Buy
272,707
+34,963
+15% +$387K ﹤0.01% 3068
2021
Q2 		$2.54M Buy
237,744
+91,104
+62% +$993K ﹤0.01% 3190
2021
Q1 		$1.93M Buy
146,640
+14,128
+11% +$232K ﹤0.01% 3266
2020
Q4 		$2.69M Buy
+132,512
New +$2.54M ﹤0.01% 2918

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management's FHTX Position: Q2 2026 in Review

Geode Capital Management increased its Foghorn Therapeutics (FHTX) stake by 7.4% in Q2 2026, buying an estimated $278K and bringing the position to 910,866 shares worth $4.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2976.

Geode Capital Management first reported a position in FHTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $7.94M in Q4 2021. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Geode Capital Management held 910,866 shares of Foghorn Therapeutics worth $4.45M as of Q2 2026.
  • Geode Capital Management bought 62,694 Foghorn Therapeutics shares in Q2 2026, an estimated $278K.
  • Foghorn Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2976 holding.
  • Geode Capital Management first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Geode Capital Management's Foghorn Therapeutics position peaked at $7.94M in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.